

**ASX RELEASE**

**31 July 2019**

**Shareholder Participation in Rights Issue Supports Clinical-Enabling Studies**

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) Rights Issue closed on Friday 26 July 2019 having been well supported by shareholders in both Australia and New Zealand.

The Rights Issue offered eligible shareholders the right to acquire new shares at A\$0.10 per share (NZ\$0.11 per share) on a 1 for 2 basis with free attaching options on the basis of 1 option for every 2 new shares applied for. The options will have an exercise price of A\$0.15 and an expiry date of 30 June 2022.

Total funds raised from the Rights Issue were as follows:

	Number of Shares Subscribed For	Total Amount Raised
Australia	6,054,058	A\$605,405.80
New Zealand	793,224	NZ\$87,254.64

The Board wishes to thank shareholders for their support of the Rights Issue.

The resulting Rights Issue shortfall was 15,464,679 shares or \$1,546,468.

In addition to the Rights Issue the Company has also undertaken the following to raise funds as part of a capital raising strategy announced to the market on 12 June 2019:

- i. An Initial Placement of 3,600,000 ordinary shares @ \$0.10 per share to raise \$360,000 which was completed in June 2019;
- ii. A Directors and Management Placement of 1,700,000 ordinary shares @ \$0.10 per share to raise \$170,000 which is subject to shareholder approval at the Company’s Annual General Meeting to be held on Friday 30 August 2019.

As a result of the capital raisings above, and assuming shareholders approve the Directors placement, the Company will have \$1.5 million in cash available. The Company will now look to advance further preclinical studies of its lead drug candidate AMP945 with the aim of commencing a Phase 1 study in early 2020.

- End -

**For Further Information**

Dr. John Lambert  
Chief Executive Officer  
[john@ampliatx.com](mailto:john@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

Suite 226, 55 Flemington Road, North Melbourne, VIC 3051

Email [info@ampliatx.com](mailto:info@ampliatx.com)

[www.ampliatx.com](http://www.ampliatx.com)